AI

Ainos IncNASDAQ AIMD Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Dec, 2024

Last price

Market cap $B

0.004

Micro

Exchange

XNAS - Nasdaq

AIMD Stock Analysis

AI

Uncovered

Ainos Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-66/100

Low score

Market cap $B

0.004

Dividend yield

Shares outstanding

20.012 B

Ainos, Inc. is a healthcare company engaged in the discovery and development of pharmaceutical and biotech products. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The firm is researching for the treatment of human disease indications, including Sjogren’s syndrome, thrombocytopenia, and other indications using interferon-alpha. The firm is also developing and manufacturing point-of-care testing rapid test kit products that include diagnostics for COVID-19, pneumonia, vaginal infection and helicobacter pylori bacterial infection. Its business units include Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. Medical Device Division is developing an insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Preventative Medicine Division is focused on SRNA-based therapeutics.

View Section: Eyestock Rating